Belgium’s KWARTS, a customer data platform for the Life Sciences sector, gets acquired by DLIMI

Copenhagen-based DLI Market Intelligence (DLIMI), a company that provides data, strategies, and technologies to the pharmaceutical industry, announced on Wednesday that it has acquired Belgium’s KWARTS, an AI-driven customer data platform.

The transfer will be completed in the first quarter of 2023. With this acquisition, KWARTS CEO and Founder Bart Van Proeyen will end his seven-year innovation process with the Limburg scale-up.

Bart Van Proeyen says, “It is a huge recognition for the work done by our team, which also includes experts from Hasselt University. Over the years we have been supported by loyal customers, commercial partners and governmental bodies such as VLAIO and EIT Health – but also private investors, including Volta Ventures, business angels and imec.istart.”

What does KWARTS offer?

Founded in 2016 by Bart Van Proeyen, KWARTS helps organisations to become more data-driven. It is a technology company behind A-Inside, an innovative customer data platform for the Life Sciences industry.

A-Inside is an AI-driven customer data platform which helps companies to centralise and analyse data streams and map out the customer journey. This also helps in spending more time on meaningful customer engagement and less time on data crunching.

The company says, “Our intelligence engine predicts the next best action for every single customer, and lists the key priorities for sales and marketing, in each specific client’s context. In this way, you can optimise customer journeys at scale.”

The A-Inside platform was developed within the framework of a VLAIO project in cooperation with the BIARU cell at Hasselt University, and is based on scientific research.

KWARTS has already completed projects in Europe and Asia, and aims to grow in the US in the coming future.

Aim of this acquisition

After the KWARTS platform’s initial roll-out was a success, including at Takeda Pharmaceutical Company, the company is focused on growth and aims to expand worldwide commercialisation within the existing market trends.

Bart Van Proeyen says, “Within the board, we have compared various growth scenarios and evaluated with a critical eye how we could give our data platform the best growth opportunities. The search for a strategic partner with an existing commercial network, that also has qualitative market data available with which we could further increase confidence in our AI algorithms, proved to be a crucial factor for success. Such a partner was found with DLIMI, which ultimately led to the sale to the Danish company.”

The Danish acquirer says it is in a great position to improve the quality of insights and illustrate the financial effect by unleashing the AI algorithms of KWARTS on important data regarding medical communication, prescriptions, and treatments that DLIMI has at its disposal.

As a result, DLIMI believes, the software will grow even more powerful, housed under a new roof with all the strategic components it needs to continue playing a leading role.

Bart Van Proeyen says, “Because DLIMI is part of The Danish Association of the Pharmaceutical Industry (including Amgen, Lundbeck, Pfizer and Novartis on its governing body), we believe that it is the right party to increase the adoption of AI-driven working in the industry.”

DLIMI is focused on the Nordic region, where finding doctors is now quite challenging and where the demand for this solution is perhaps the highest.

About DLI Market Intelligence

DLIMI is a data-based partner that helps life science companies in Denmark and the Nordics realise their potential, ultimately for the benefit of patients and society. It claims to have 40+ years of experience in investigating market dynamics, delivering market insights, and helping in the market development of its clients.

DLIMI is an independent unit of Danish Medicine Information (DLI). DLI is owned by the Pharmaceutical Industry Association (Lif). Its research-based projects are often carried out in collaboration with authorities, universities and other research organisations.

Statistics Denmark and the Danish Health Data Authority have also granted the company access to the Research Machine’s data. This indicates that DLIMI’s research activities, data security expertise, and registry information have all received governmental approval.

The company’s ultimate goal is for the discoveries made via its research and initiatives to contribute to the open, shared body of knowledge that advances the pharmaceutical and healthcare industries.